Evaluation of Renal Anemia Therapy in Chronic Kidney Disease Patients Undergoing Hemodialysis in Hospital
DOI:
https://doi.org/10.37287/ijghr.v8i1.530Keywords:
anemia, blood transfusion, chronic kidney disease, ESAs, hemodialysis , iron therapyAbstract
End-stage chronic kidney disease (CKD) requiring hemodialysis is often complicated by anemia. Renal anemia in CKD-HD patients can affect quality of life and worsen prognosis. Anemia therapy involves erythropoiesis-stimulating agents (ESAs), iron supplements, and blood transfusions, but evaluation of their effectiveness at Dr. Loekmono Hadi Kudus Regional Hospital is still limited. This study aims to evaluate the anemia profile and the effectiveness of anemia therapy in PGK-HD patients at Dr. Loekmono Hadi Kudus Regional Hospital. This study used a quantitative descriptive method with purposive sampling technique in 93 CKD-HD patients with hemoglobin levels ≤ 10 g/dL. Data were collected through a review of electronic medical records and analyzed using descriptive statistics. Most CKD-HD patients had moderate (48%) and severe (43%) anemia. 90% of patients received ESA therapy, with 62% receiving PRBC transfusions and 47% combination therapy. Iron status analysis showed that many patients required supplemental iron therapy. Anemia in CKD-HD patients at Dr. Loekmono Hadi Kudus Regional Hospital requires more optimal management with routine monitoring of iron status. Further evaluation of ESA and iron therapy is needed to improve patient quality of life and prevent further complications.
References
Andhika, R. G., Afiatin, Supriyadi, R., Bandiara, R., Sukesi, L., Sudarmadi, A. P., & Sofiatin, Y. (2025). One-year survival of end-stage kidney disease patients undergoing hemodialysis in Indonesia. International Journal of Nephrology and Renovascular Disease. https://doi.org/10.2147/IJNRD.S508012
Badura, K., et al. (2024). Anemia of Chronic Kidney Disease—A Narrative Review. Journal of Clinical Medicine, 12(6), 1191. https://doi.org/10.3390/jcm12061191
Bhandari, S., et al. (2025). UK kidney association clinical practice guideline: update of anemia management in chronic kidney disease. BMC Nephrology, 26(1), 1-15. https://doi.org/10.1186/s12882-025-04115-1
Hasanah, D., et al. (2023). Analisis Faktor-Faktor Risiko Terjadinya Penyakit Gagal Ginjal Kronik Pada Pasien Hemodialisis. Lampung. Jurnal Akper Dharma Wacana, 8(2), 159–166.
Hemmige, V., et al. (2024). Geographic dialysis facility density and early dialysis initiation. JAMA Network Open, 7(1), e2350009. https://doi.org/10.1001/jamanetworkopen.2023.50009
Jia, X., et al. (2023). Update of dialysis initiation timing in end-stage kidney disease patients: Is it a resolved question? BMC Nephrology, 24, 333. https://doi.org/10.1186/s12882-023-03184-4
Kemenkes RI. (2023). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1634/2023 Tentang Pedoman Nasional Pelayanan Kedokteran (PNPK) Tatalaksana Ginjal Kronik.
Khan, A., et al. (2024). Prevalence and management of anemia and impact on quality of life in patients with chronic kidney disease. Journal of Renal Care, 50(2), 115-122. https://doi.org/10.1111/jorc.12345
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. (2025). KDIGO 2025 Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International Supplements, 15(1), 1-100. https://doi.org/10.1016/j.kisup.2024.11.001
Ogolla, C. O., et al. (2025). Impact of iron deficiency and erythropoiesis-stimulating agents on anemia management in chronic kidney disease. Journal of Clinical Medicine, 14(5), 1234. https://doi.org/10.3390/jcm14051234
Pernefri. (2020). 13th Annual report of Indonesian renal registry 2020. Indonesian Renal Registry (IRR).
Pham, H. V., Tran, N. V., Thai, T. T., & Tran, H. T. B. (2024). Gender and age differences in KDIGO treatment targets among people on maintenance hemodialysis. Medicine, 103(4), e37088. https://doi.org/10.1097/MD.0000000000037088
Prapaiwong, P., et al. (2025). Determinants of anemia among patients with chronic kidney disease: A cross-sectional study. Journal of Nephrology, 28(1), 45-52. https://doi.org/10.1007/s40620-024-01567-8
Portolé, J. (2013). The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol, 14(2).
Portolé, J., Martín, L., Broseta, J. J., & Cases, A. (2021). Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments to Future Agents. Front. Med., 8(6).
Sabanayagam, C., Xu, D., Ting, D. S. W., Nusinovici, S., Banu, R., Hamzah, H., & Wong, T. Y. (2020). A deep learning algorithm to detect chronic kidney disease from retinal photographs in community-based populations. The Lancet Digital Health, 2(6), e295-e302. https://doi.org/10.1016/s2589-7500(20)30063-7.
Siagian, K. N., & Damayanty, A. E. (2018). Artikel Penelitian Identifikasi Penyebab Penyakit Ginjal Kronik Pada Usia Dibawah 45 Tahun di Unit Hemodialisis Rumah Sakit Ginjal Rasyida Medan Tahun 2015. Jurnal Kedokteran Anatomica (Anatomica Medical Journal), 1(3), 159–166.
Sofue, T., Nakagawa, N., Kanda, E., Nagasu, H., Matsushita, K., Nangaku, M., et al. (2020). Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-PGK-DB). PLoS ONE, 15(7). https://doi.org/10.1371/journal.pone.0236132.
Sugiyono. (2019). Metodologi Penelitian Kuantitatif dan Kualitatif Dan R&D. Bandung: ALFABETA.
U.S. FDA approves Akebia's anemia drug. (2024, March 28). Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-akebias-anemia-drug-2024-03-28/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
